Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. (July 2015)

• Record Type: Journal Article
• Authors: Warnke, Clemens; Stettner, Mark; Lehmensiek, Vera; Dehmel, Thomas; Mausberg, Anne K; von Geldern, Gloria; Gold, Ralf; Kümpfel, Tania; Hohlfeld, Reinhard; Mäurer, Mathias; Stangel, Martin; Straeten, Vera; Limmroth, Volker; Weber, Thomas; Kleinschnitz, Christoph; Wattjes, Mike P; Svenningsson, Anders; Olsson, Tomas; Hartung, Hans-Peter; Hermsen, Derik; Tumani, Hayrettin; Adams, Ortwin; Kieseier, Bernd C
• Is Part Of: Multiple sclerosis. Volume 21:Number 8(2015)
• Page Start: 1036
• Page End: 1044
• Publication Date: 2015-07
• Subjects: Progressive multifocal leukoencephalopathy -- JC virus -- natalizumab -- Tysabri -- multiple sclerosis -- disease-modifying therapies -- immunosuppression; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458514556296
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: Natalizumab for multiple sclerosis (MS) increases the risk of progressive multifocal leukoencephalopathy (PML). Objective: We aimed to assess the effect of natalizumab on cellular composition and functional B cell parameters including patients with natalizumab-associated PML ( n =37). Methods: Cellular composition by flow cytometry, levels of immunoglobulin (Ig)G/IgM by immunonephelometry, and oligoclonal bands by isoelectric focusing were studied in blood and cerebrospinal fluid. Results: In MS patients treated with natalizumab without PML ( n =59) the proportion of CD19+ B cells was higher in blood, but lower in cerebrospinal fluid compared with MS patients not treated with natalizumab ( n =17). The CD4/CD8-ratio in cerebrospinal fluid was lower, and IgG and IgM levels as well as the IgG index dropped in longitudinal samples during natalizumab therapy. Oligoclonal bands persisted, but the total amount of the intrathecally produced IgG fraction, and the polyclonal intrathecal IgG reactivity to measles, rubella, and zoster declined. At the time of diagnosis of PML patients with natalizumab-associated PML had low total IgG levels in blood and cerebrospinal fluid. Conclusions: Natalizumab impacts B and T cell distribution and exerts an inhibitory effect on surrogates of B cell function in periphery and in cerebrospinal fluid, potentially contributing to the increased risk of developing PML.